# Amgen: Phase 2 study closed enrollment, 252 enrolled (Small Cell Lung Cancer (SCLC))

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Amgen |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC |
| NCT ID | NCT06745323 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Small Cell Lung Cancer (SCLC) |
| Intervention types | drug |
| Target enrollment | 252 |
| Site countries | United States, Argentina, Australia, Belgium, Brazil, China, France, Germany, Greece, Italy, Japan, South Korea |
| Posted | 2024-12-20 |
| Planned start | 2025-02-26 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 252 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06745323). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.